In 2025, Serena Williams set a precedent: celebrity-led conversation around prescription drugs

In August 2025, Serena Williams publicly disclosed her use of GLP-1 medicines for weight management through a partnership with Ro, a U.S. telehealth company. The announcement pulled a clinical topic into mainstream discourse and made it easier for patients and clinicians to talk about it.

The disclosure didn't read like a typical celebrity endorsement. Williams placed GLP-1s inside a supervised medical framework - consultation, monitoring, a structured patient pathway - rather than positioning the drugs as a quick fix.

It landed because the appetite was already there. When someone of Williams's stature speaks candidly, stigma drops and people seek professional advice.

For brands the lesson is clear. Celebrities can normalise. They can remove barriers. But the information has to stay accurate, balanced, and aligned with product labelling. Benefits and risks need to ride together with clear disclosures.

The model: define talent roles cleanly. Celebrities humanise. Healthcare professionals explain mechanism and safety. Patient advocates share lived experience. Get creative and regulatory aligned before production. Plan community management for after launch - for the questions and the misinformation.

Measurement should clear engagement and reach for things that actually matter: qualified traffic to safety-information pages, completed consultations, intent to talk to a clinician. Williams showed that celebrity can sit alongside clinical responsibility. The brands that build the full ecosystem around that - oversight, balance, disclosure, measurement - will win the next decade of healthcare marketing.